Fruit Fly Sleep Protein Produces Peptides That Inhibit Drug-Resistant Bacteria

A protein that puts fruit flies to sleep may also supply a new way to attack drug-resistant bacteria. Researchers at the University of Tsukuba and collaborating institutions have identified several short antimicrobial peptides derived from Nemuri, a sleep-inducing protein in the fruit fly Drosophila melanogaster. In lab tests, the peptides inhibited the growth of a wide range of microorganisms, including clinically important drug-resistant bacterial strains. The study is published in Nature Communications.

Against two major pathogens, the peptides did more than slow growth. In Escherichia coli and Staphylococcus aureus, they showed bactericidal activity — they killed the bacteria — at concentrations close to those required to inhibit growth. That's a useful property in a candidate antimicrobial, because a drug that only pauses bacteria can let an infection restart when the dose fades.

The mechanism is the part that doesn't look like existing antibiotics. The peptides enter bacterial cells and accumulate in ribosome- and RNA-rich regions, the cell's protein-building machinery. They interact broadly with RNA molecules and ribosomal surfaces and induce a condensation-like remodeling of those regions. The remodeling reduces ribosomal mobility and suppresses protein synthesis across the cell. At the concentrations that killed bacteria, the researchers detected no substantial disruption of the bacterial membrane, which is how many older peptide antibiotics work.

Early safety signs are narrow but real. The peptides showed low toxicity toward cultured insect and mammalian cells in the lab. That result comes from dishes, not bodies, and it doesn't predict what the peptides would do to a patient's own cells, gut microbes or kidneys at a working dose. The team is explicit that the work is a starting point.

The context is a resistance problem that keeps outrunning the drug pipeline. Bacteria that survive standard antibiotics force doctors toward last-line drugs, longer hospital stays and, in the worst cases, infections with no working treatment. A compound family that attacks protein synthesis through physical organization, rather than through the targets current drugs bind, gives medicinal chemists a different surface to work on. The paper's authors are Suguru Nishinami and colleagues, and the full record is in Nature Communications (2026), DOI 10.1038/s41467-026-78960-5.

What happens next is the standard hard part. The peptides still need evaluations of efficacy and safety in animal models of bacterial infection before anyone can talk about a drug. Many lab-stage antimicrobials fail there, on absorption, stability or toxicity. The Nemuri result doesn't change a prescription today. It adds a mechanism to the short list of ones that drug-resistant bacteria haven't already learned to beat.